Tag: GlobeNewswire

Final delivery and training under LAND 159 Tranche 1 supports Australian Army sniper capability

ARLINGTON, Va., Oct. 05, 2026 (GLOBE NEWSWIRE) — Leonardo DRS, Inc. (Nasdaq: DRS) has completed final training and delivery for the Improved Night/Day Observation Device (INOD) Block III thermal weapon sights provided to the Australian Army under the LAND 159 Tranche 1 program.

The INOD Block III is a clip-on thermal weapon sight designed to help snipers and special operations forces detect, identify and engage targets in low-light and degraded visual conditions, including darkness, smoke, haze and adverse weather. Mounted in front of an existing direct-view optic, the system is designed to preserve the operator’s zeroed scope and is compatible with magnifications from 5x to greater than 25x. 

“Completing delivery and training for the Australian Army is an important milestone for our team,” said Jerry Hathaway, senior vice president and general manager of Leonardo DRS Electro-Optical and Infrared Systems business unit. “The INOD Block III provides a thermal sighting capability intended to support sniper operations in demanding conditions, and the training helps ensure personnel are prepared to operate and maintain the system.” 

The sight uses a micro-cooled, 640-by-480 mid-wave infrared focal plane array to provide thermal imagery and target discrimination in conditions that can limit conventional optics. 

Designed for sustained field use, the system uses lithium batteries with hot-swap capability, allowing battery changes without interrupting operation. The sight can also use external power for extended static-surveillance tasks. A rear-facing focus knob, wired remote control and glove-compatible, one-handed operation support use in field conditions. 

For the Australian Army, the LAND 159 Tranche 1 acquisition represents a step-change in long-range lethality. Australian snipers will now carry the same generation of thermal sight currently fielded with U.S. Army Special Operations Forces, strengthening interoperability with Australia’s primary alliance partner across joint and coalition operations. Beyond the hardware, DRS provided hands-on training to Australian Army personnel to support operation and maintenance of the systems. The company is a provider of individual weapon sights and thermal targeting systems to the U.S. Army. The INOD family is part of DRS’s thermal sighting portfolio, which also includes the Family of Weapon Sights program. 

Australian defense company NIOA is the prime contractor for LAND 159 Tranche 1 and managed local program coordination and delivery logistics on behalf of the Australian Army. 

About Leonardo DRS

Leonardo DRS, Inc. (Nasdaq: DRS) is at the forefront of developing transformative defense technologies using its proven agility and delivering innovative solutions for U.S. national security customers and allies worldwide. We specialize in rapidly providing high-performance, multi-domain capabilities across next-generation advanced sensing, network computing, force protection, and electric power and propulsion. Our reputation as a trusted provider is built on a continuous focus on practical innovation, delivering quality, and meeting our customers’ most demanding mission requirements. For further information on our complete range of capabilities, visit www.LeonardoDRS.com.

Forward-Looking Statements

This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Those statements reflect current expectations, assumptions and estimates of future performance and economic conditions. The company cautions investors that any forward-looking statements which include contract values, contract performance and our development and production of products are subject to risks and uncertainties that may cause actual results and future trends to differ materially from those matters expressed in or implied by such forward-looking statements.

Leonardo DRS Investor Relations Contact
Camilla Yanushevsky
Director, Investor Relations
+1 571 309 8216
investorrelations@drs.com

Leonardo DRS Media Contact
Charles Jones
Director, Marketing and Corporate Communications
+1 571-737-8800
charles.jones@drs.com  

TORONTO, Oct. 05, 2026 (GLOBE NEWSWIRE) — (TSX: PIC.A; PIC.PR.A) Premium Income Corporation has declared monthly distributions payable on October 30, 2026 to shareholders of record on October 15, 2026 in the following amounts per share:

Share Class	Ticker	Amount Per Share
Class A Shares	PIC.A	$0.09000
Preferred Shares	PIC.PR.A	$0.10625

To the extent that any portion of the distributions are ordinary taxable dividends and not capital gains dividends, they will be eligible dividends.

For further information, please contact Investor Relations at 416.681.3966, toll free at 1.800.725.7172, email at info@mulvihill.com or visit www.mulvihill.com

John Germain, Senior Vice-President & CFO	Mulvihill Capital Management Inc. 25 King Street West Commerce Court North Suite 2110, Box 48 Toronto, Ontario, M5L 1A1

Commissions, trailing commissions, management fees and expenses all may be associated with investment funds. Please read the prospectus before investing. Investment funds are not guaranteed, their values change frequently and past performance may not be repeated.

TORONTO, Oct. 05, 2026 (GLOBE NEWSWIRE) — (TSX: SPFD) Mulvihill Enhanced Split Preferred Share ETF has declared a monthly cash distribution in the amount of $0.08333 per unit, payable on November 6, 2026 to unitholders of record on October 30, 2026.

For further information, please contact Investor Relations at 416.681.3966, toll free at 1.800.725.7172, email at info@mulvihill.com or visit www.mulvihill.com.

John Germain, Senior VP & CFO	Mulvihill Capital Management Inc.
	25 King Street West
	Commerce Court North
	Suite 2110, Box 48
	Toronto, Ontario, M5L 1A1

Commissions, trailing commissions, management fees and expenses all may be associated with exchange traded funds (ETFs). Please read the prospectus before investing. ETFs are not guaranteed, their values change frequently, and past performance may not be repeated. There are risks involved with investing in ETFs. Please read the prospectus for a complete description of risks relevant to ETFs. Investors may incur customary brokerage commissions in buying or selling ETFs.

TORONTO, Oct. 05, 2026 (GLOBE NEWSWIRE) — (TSX: CBNK) Mulvihill Canadian Bank Enhanced Yield ETF has declared a monthly cash distribution in the amount of $0.12 per unit, payable on November 6, 2026, to unitholders of record on October 30, 2026.
  
For further information, please contact Investor Relations at 416.681.3966, toll free at 1.800.725.7172, email at info@mulvihill.com or visit www.mulvihill.com.

John Germain, Senior Vice-President & CFO	Mulvihill Capital Management Inc. 25 King Street West Commerce Court North Suite 2110, Box 48 Toronto, Ontario, M5L 1A1

Commissions, trailing commissions, management fees and expenses all may be associated with investment funds. Please read the prospectus before investing. Investment funds are not guaranteed, their values change frequently and past performance may not be repeated.

TORONTO, Oct. 05, 2026 (GLOBE NEWSWIRE) — (TSX: MPY) Mulvihill Premium Yield has declared a monthly cash distribution for its ETF Class in the amount of $0.07 per unit, payable on November 6, 2026 to unitholders of record on October 30, 2026.

For further information, please contact Investor Relations at 416.681.3966, toll free at 1.800.725.7172, email at info@mulvihill.com or visit www.mulvihill.com.

John Germain, Senior Vice-President & CFO	Mulvihill Capital Management Inc. 25 King Street West Commerce Court North Suite 2110, Box 48 Toronto, Ontario, M5L 1A1

Commissions, trailing commissions, management fees and expenses all may be associated with investment funds. Please read the prospectus before investing. Investment funds are not guaranteed, their values change frequently and past performance may not be repeated.

TORONTO, Oct. 05, 2026 (GLOBE NEWSWIRE) — (TSX: PGIC; PGIC.PR.A) Premium Global Income Split Fund has declared monthly distributions payable on October 30, 2026 to shareholders of record on October 15, 2026 in the following amounts per share:

Share Class	Ticker	Amount Per Share
Class A Shares	PGIC	$0.08000
Preferred Shares	PGIC.PR.A	$0.06250

To the extent that any portions of the distributions are ordinary taxable dividends and not capital gain dividends, they are eligible dividends.

For further information, please contact Investor Relations at 416.681.3966, toll free at 1.800.725.7172, email at info@mulvihill.com or visit www.mulvihill.com.

John Germain, Senior Vice-President & CFO	Mulvihill Capital Management Inc. 25 King Street West Commerce Court North Suite 2110, Box 48 Toronto, Ontario, M5L 1A1

Commissions, trailing commissions, management fees and expenses all may be associated with investment funds. Please read the prospectus before investing. Investment funds are not guaranteed, their values change frequently and past performance may not be repeated.

ORIC-259 is a potential first-in-class small molecule mRNA degrader targeting CIP2A, a previously undruggable target

Cancer Research UK to fully fund, sponsor, design, and execute CTA-enabling studies and Phase 1/2 clinical development

ORIC retains exclusive option to reacquire rights to ORIC-259 following Phase 1/2 data

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 05, 2026 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today announced an agreement with Cancer Research UK, one of the world’s largest funders of cancer research, to advance a potential first-in-class CIP2A-targeted therapy into clinical development.

Under the agreement, Cancer Research UK’s Centre for Drug Development (CDD) will fully fund, sponsor, design, and execute CTA-enabling studies and early clinical development of ORIC-259 for patients with cancer. ORIC retains an option to reacquire rights to ORIC-259 following Phase 1/2 data, with Cancer Research UK eligible to receive downstream milestone payments and royalties.

Cancerous Inhibitor of PP2A (CIP2A) is a protein that contributes to the development and progression of many cancer types due to its role in protein phosphorylation, mitosis, and DNA damage response. ORIC-259 is a potent, selective, orally bioavailable small molecule degrader of CIP2A mRNA. This potential first-in-class mRNA degrader is designed to modify mRNA splicing to incorporate a premature stop codon, leading to mRNA degradation and loss of CIP2A protein, which is critical for cell proliferation and survival of cancers with homologous recombination deficiency (HRD). Promising preclinical data highlight robust antitumor activity in PARP inhibitor sensitive and resistant settings, indicating broad potential for patients with HRD cancers, and supports the path to clinical development for ORIC-259.

“We are excited to partner with Cancer Research UK to advance ORIC-259, a potential first-in-class CIP2A-targeted therapy, into the clinic,” said Lori Friedman, PhD, chief scientific officer. “Cancer Research UK’s proven expertise and capabilities in developing innovative cancer therapies make it an ideal partner for the program, while this structure allows us to remain disciplined in allocating our internal resources to our late-stage clinical pipeline.”

“ORIC-259 represents an innovative approach to targeting CIP2A, a protein with significant potential in cancer but one that has proven difficult to drug,” said Lars Erwig, Director of the CDD. “We share ORIC’s mission to overcome treatment resistance in cancer, and we look forward to applying our expertise to explore new treatment options for patients.”

About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) rinzimetostat, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib, a brain-penetrant inhibitor targeting EGFR exon 20 insertion and EGFR atypical mutations, being developed for NSCLC. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.

About Cancer Research UK’s Centre for Drug Development
Cancer Research UK has an impressive record of developing novel treatments for cancer. The Cancer Research UK Centre for Drug Development has been pioneering the development of new cancer treatments for 30 years. It has completed over 170 clinical trials designed to explore potential new anti-cancer agents in patients. Six of these new agents have made it to market, including temozolomide for brain cancer, abiraterone for prostate cancer and rucaparib for ovarian cancer. www.cruk.org.uk/cdd

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding a potential first-in-class CIP2A-targeted therapy; the potential benefits of ORIC-259 and the agreement with Cancer Research UK; ORIC’s option to reacquire rights to ORIC-259 following Phase 1/2 data; and statements by the director of the CDD and the company’s chief scientific officer. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon ORIC’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics; ORIC’s or Cancer Research UK’s ability to develop, initiate or complete preclinical studies and clinical trials for, obtain approvals for and commercialize ORIC-259; changes in ORIC’s or Cancer Research UK’s plans to develop ORIC-259; the potential for preclinical studies or clinical trials of ORIC-259 to differ from prior preclinical, initial, interim, preliminary or expected results; negative impacts of health emergencies, economic instability or international conflicts on ORIC’s or Cancer Research UK’s operations, including preclinical studies and clinical trials; the risk of the occurrence of any event, change or other circumstance that could give rise to the termination of the agreement with Cancer Research UK; the potential market for ORIC-259, and the progress and success of competing therapeutics currently available or in development; ORIC’s ability to raise any additional funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries; ORIC’s reliance on third parties, including contract manufacturers and contract research organizations; ORIC’s ability to obtain and maintain intellectual property protection for ORIC-259 and its other product candidates; the loss of key scientific or management personnel; competition in the industry in which ORIC operates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in ORIC’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 3, 2026, and ORIC’s future reports to be filed with the SEC. These forward-looking statements are made as of the date of this press release, and ORIC assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

Contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com

TORONTO, Oct. 05, 2026 (GLOBE NEWSWIRE) — (TSX: MBNK) Mulvihill Canadian Bank ETF has declared a monthly cash distribution in the amount of $0.05 per share, payable on November 6, 2026, to shareholders of record on October 30, 2026.
  
For further information, please contact Investor Relations at 416.681.3966, toll free at 1.800.725.7172, email at info@mulvihill.com or visit www.mulvihill.com.

John Germain, Senior Vice-President & CFO	Mulvihill Capital Management Inc. 25 King Street West Commerce Court North Suite 2110, Box 48 Toronto, Ontario, M5L 1A1

Commissions, trailing commissions, management fees and expenses all may be associated with investment funds. Please read the prospectus before investing. Investment funds are not guaranteed, their values change frequently and past performance may not be repeated.

TORONTO, Oct. 05, 2026 (GLOBE NEWSWIRE) — (TSX: PFRD) Mulvihill Split Preferred Share ETF has declared a monthly cash distribution in the amount of $0.11667 per share, payable on November 6, 2026, to shareholders of record on October 30, 2026.

For further information, please contact Investor Relations at 416.681.3966, toll free at 1.800.725.7172, email at info@mulvihill.com or visit www.mulvihill.com.

John Germain, Senior Vice-President & CFO

Mulvihill Capital Management Inc. 25 King Street West Commerce Court North Suite 2110, Box 48 Toronto, Ontario, M5L 1A1

Commissions, trailing commissions, management fees and expenses all may be associated with investment funds. Please read the prospectus before investing. Investment funds are not guaranteed, their values change frequently and past performance may not be repeated.

RED BANK, N.J., Oct. 05, 2026 (GLOBE NEWSWIRE) — OceanFirst Financial Corp. (NASDAQ: OCFC) (the “Company”), the holding company for OceanFirst Bank N.A. (the “Bank”), today announced that it will release its third quarter 2026 financial results after the market close on Tuesday, October 27, 2026. Management will host a conference call to discuss the results at 8:00 a.m. Eastern Time on Wednesday, October 28, 2026.

To participate by phone, dial 1-833-461-5787 (U.S. toll-free) and enter meeting ID 545140997. A live, listen-only webcast will be available on the Company’s investor relations website at https://ir.oceanfirst.com/ or directly at https://events.q4inc.com/attendee/545140997. Webcast participants should register at least fifteen minutes before the call. A replay of the webcast will be available at the same link after the call.

OceanFirst Financial Corp.’s subsidiary, OceanFirst Bank N.A., founded in 1902, is a $23 billion regional bank serving business and retail customers throughout New Jersey, New York, Long Island, and the major metropolitan areas from Massachusetts through Virginia. OceanFirst Bank delivers commercial and residential financing, treasury management, trust and asset management, and deposit services and is one of the largest and oldest community-based financial institutions headquartered in New Jersey. To learn more about OceanFirst, please visit us at www.oceanfirst.com.

Forward-Looking Statements

In addition to historical information, this press release contains certain forward-looking statements within the meaning of the federal securities laws, which are based on certain assumptions and describe future plans, strategies and expectations of the Company. Forward-looking statements may be identified by the use of the words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “believe,” “seek,” “strategy,” “future,” “opportunity,” “may,” “could,” “target,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” or similar expressions that predict or indicate future events or trends or that are not statements of historical matters, although not all forward-looking statements contain such identifying words. These statements are based on various assumptions, whether or not identified in this document, and on the current expectations of the Company’s management and are not predictions of actual performance, and, as a result, are subject to risks and uncertainties. These forward-looking statements are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict, may differ from assumptions and many are beyond the control of the Company. The forward-looking statements are intended to be subject to the safe harbor provided by Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995. Factors that could have a material adverse effect on the operations of the Company and its subsidiaries include, but are not limited to: changes in interest rates, inflation, general economic conditions, including potential recessionary conditions, levels of unemployment in the Company’s lending area, real estate market values in the Company’s lending area, potential goodwill impairment, natural disasters, potential increases to flood insurance premiums, the current or anticipated impact of military conflict, terrorism or other geopolitical events, the imposition of tariffs or other domestic or international governmental policies, trade restrictions and retaliatory measures impacting the Company’s borrowers and the broader economy, the effects of a potential future federal government shutdown, debt ceiling impasses or fiscal uncertainty, the level of prepayments on loans and mortgage-backed securities, legislative/regulatory changes, monetary and fiscal policies of the U.S. Government, including policies of the U.S. Treasury and the Board of Governors of the Federal Reserve System, the quality or composition of the loan or investment portfolios, demand for loan products, deposit flows, the availability of low-cost funding, changes in liquidity, including the size and composition of the Company’s deposit portfolio and the percentage of uninsured deposits in the portfolio, changes in capital management and balance sheet strategies and the ability to successfully implement such strategies, competition, demand for financial services in the Company’s market area, our ability to enter into new markets and capitalize on growth opportunities, the adequacy of and changes in the economic assumptions and methodology for computing the allowance for credit losses, availability of capital, competition, our ability to maintain and increase market share and control expenses, changes in investor sentiment and consumer spending, borrowing and savings habits, changes in accounting principles, risks associated with cybersecurity threats, data breaches, ransomware attacks, or other failures in the Company’s operational or security systems and infrastructure, including the risks arising from the Company’s dependence on third-party service providers and vendors, the failure to maintain current technologies and the operational risks associated with the adoption of artificial intelligence and other emerging technologies, failure to retain or attract employees, the impact of pandemics on our operations and financial results and those of our customers and the Bank’s ability to successfully integrate acquired operations. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of OceanFirst’s Annual Report on Form 10-K for the year ended December 31, 2025, and other documents filed by OceanFirst from time to time with the U.S. Securities and Exchange Commission (the “SEC”). The Company does not undertake, and specifically disclaims any obligation, to publicly release the result of any revisions that may be made to any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

Investor Relations Inquiries:
OceanFirst Financial Corp.
Alfred Goon
SVP Corporate Development and Investor Relations
investorrelations@oceanfirst.com

Company Contact:

Patrick S. Barrett
Chief Financial Officer
OceanFirst Financial Corp.
1.888.623.2633 ext. 27507
Email: pbarrett@oceanfirst.com